A Study Of PF-06664178 In Patients With Advanced Solid Tumors

Back to Search
Print
Bookmark Trial

NCT02122146

Last updated date
Back to Search
Print
Bookmark Trial
FOR MORE INFORMATION
Study Location
Keck Hospital of USC
Los Angeles, California, 90033, United States
See other locations
Contact
1-800-718-1021
[email protected]
Related Links

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Neoplasms
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Diagnosis of solid tumor that is advanced/metastatic and resistant to standard therapy or for whom no standard therapy is available

- Performance Status of 0 or 1

- Adequate bone marrow, kidney and liver function

- Part 2 includes target expressing NSCLC, ovarian or breast cancer patients

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Brain metastases requiring steroids


- Major surgery, radiation therapy, or systemic anti-cancer therapy within 4 weeks of
study treatment start (6 weeks for mitomycin C or nitrosoureas)


- Active and clinically significant bacterial, fungal, or viral infection

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

Call Now

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Advanced Search

Based on your search, you may also be interested in

NeoplasmsStudy To Evaluate The Safety, Pharmacokinetics, And Pharmacodynamics Of PF-00299804 In Patients With Advanced Solid Tumors
NCT00225121
  1. Los Angeles, California
  2. Los Angeles, California
  3. Los Angeles, California
  4. Santa Monica, California
  5. Santa Monica, California
  6. Aurora, Colorado
  7. Boston, Massachusetts
  8. Boston, Massachusetts
  9. Amsterdam,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
NeoplasmsStudy Evaluating TTI-237 in Advanced Malignant Solid Tumors
NCT00195247
  1. Scottsdale, Arizona
  2. Los Angeles, California
  3. Baltimore, Maryland
ALL GENDERS
18 Years+
years
MULTIPLE SITES
NeoplasmsStudy Evaluating MST-997 in Advanced Malignant Solid Tumors
NCT00088647
  1. New York, New York
  2. Cleveland, Ohio
  3. Nashville, Tennessee
ALL GENDERS
18 Years+
years
MULTIPLE SITES
NeoplasmsA Study In Patients With Advanced Solid Tumor
NCT00726752
  1. Kobe-shi, Hyogo-ken
ALL GENDERS
20 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE A Study Of PF-06664178 In Patients With Advanced Solid Tumors
Official Title  ICMJE A Phase 1, Dose Escalation Study Of Pf-06664178 In Patients With Locally Advanced Or Metastatic Solid Tumors
Brief Summary To assess the safety and tolerability at increasing dose levels of PF-06664178 in patients with advanced solid tumors in order to determine the maximum tolerated dose and select the recommended Phase 2 dose.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Study Design  ICMJE Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Neoplasms
Intervention  ICMJE
  • Drug: PF-06664178
    Part 1 - PF-06664178 will be administered intravenously every 21 days in cohorts of 2 or more patients starting at a dose of 0.15 mg/kg. Increases in dose will continue until MTD is determined.
  • Drug: PF-06664178
    Part 2 - patients with select tumor types (Non Small Cell Lung Cancer ovarian cancer, and breast cancer ) will be treated at the MTD selected in Part 1.
Study Arms  ICMJE Experimental: PF-06664178
Experimental
Interventions:
  • Drug: PF-06664178
  • Drug: PF-06664178
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Terminated
Actual Enrollment  ICMJE
 (submitted: August 8, 2016)		31
Original Estimated Enrollment  ICMJE
 (submitted: April 22, 2014)		130
Actual Study Completion Date  ICMJE June 2016
Actual Primary Completion Date June 2016   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Diagnosis of solid tumor that is advanced/metastatic and resistant to standard therapy or for whom no standard therapy is available
  • Performance Status of 0 or 1
  • Adequate bone marrow, kidney and liver function
  • Part 2 includes target expressing NSCLC, ovarian or breast cancer patients

Exclusion Criteria:

  • Brain metastases requiring steroids
  • Major surgery, radiation therapy, or systemic anti-cancer therapy within 4 weeks of study treatment start (6 weeks for mitomycin C or nitrosoureas)
  • Active and clinically significant bacterial, fungal, or viral infection
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT02122146
Other Study ID Numbers  ICMJE B7401001
2015-002704-84 ( EudraCT Number )
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Pfizer
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date August 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP